Shares of Peregrine Pharmaceuticals (PPHM +24.7%) bounce back hard from yesterday's selloff on...


Shares of Peregrine Pharmaceuticals (PPHM +24.7%) bounce back hard from yesterday's selloff on the back of a negative Seeking Alpha article. The stock has been a momentum darling, up nearly 340% since the end of June, mainly on optimism over its cancer drug bavituximab, as defenders of the stock argue that recent Phase II studies show the doubling of tumor response rates, a 50% increase in median progression free survival, and trends toward significant improvement in median overall survival.

From other sites
Comments (2)
  • pgg76109
    , contributor
    Comments (10) | Send Message
     
    I think they will be partnered soon and they will double the standard of care in stage four lung cancer patients. IMO this will be groundbreaking. Some think the drug is a placebo longs think its a billion dollar a year + seller. PG
    28 Aug 2012, 01:05 PM Reply Like
  • rmeissner
    , contributor
    Comments (9) | Send Message
     
    HMMM..... Peregrine hired Rob Garnick to get Bavituximab approved..Rob worked for Genentech for 24 years as head of Regulatory Approval.....Roche bought Genentech...SO, Garnick knows all the players at Roche, Garnick knows all the players at the FDA, Garnick believes strongly in Bavituximab, Peregrine is presenting at the Vienna ESMO Congress in Switzerland on September 28th.....Do you think Roche is looking at PPHM ?? I would bet on it.
    28 Aug 2012, 01:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs